ABBV-RGX-314
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABBV-RGX-314, covering 2026-02-17 to 2026-04-28. Get the full timeline:
Most recent: Clinical Trial Update: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD [Phase 2, Phase 3]